In this interview, Jordana Cohen, MD, describes the rapidly evolving landscape of ambulatory and cuffless blood pressure monitoring to Anna Gaddy, MD.

Aylin Akifova, MD, discusses new findings suggesting that felzartamab remains effective in late antibody-mediated rejection regardless of a patient's prior treatment history.

Review key research highlights from the 63rd ERA Congress featuring major study readouts, emerging data in kidney disease, and expert insights shaping clinical practice.

Drs. Joel Topf and Anna Gaddy discussed highlights of the 63rd European Renal Association Congress, including the FIND-CKD and MAJESTY trials.

Headlines include a cardiovascular kidney metabolic (CKM) syndrome guideline, a bill supporting polycystic kidney disease research, the StrongBox transplant transport container.

In this recurring Nephrology Times feature, we asked four nephrologists: How do you foster strong communication within a multidisciplinary care team?

As temperatures rise due to climate change, so do heat-related kidney illnesses, including acute kidney injury (AKI) and chronic kidney disease (CKD).

Nurse educator Jami S. Brown explores the prevalence of depression in chronic kidney disease and why mental health assessment should be part of CKD care.

The FDA has granted Priority Review to finerenone for the treatment of adults with type 1 diabetes and chronic kidney disease (CKD).

Anna Gaddy, MD, discusses recent study findings from Matthew Kaufmann, PhD, showing that transplantation with kidneys of decreased quality may be worthwhile for older adults.

Kenneth Lieberman, MD, speaks to Joel Topf, MD, about DUPLEX, a trial of sparsentan in FSGS, and the importance of proteinuria in kidney trials.

In this recurring section, Nephrology Times asked four nephrology fellows: What nephrology invention are you most hoping will exist in 10 years?

Discover research and other updates from NKF SCM26 on Nephrology Times.

Joel Topf, MD, interviews National Kidney Foundation President Kirk Campbell, MD, at the 2026 NKF Spring Clinical Meetings.

Discover research and other updates from NKF SCM26 on Nephrology Times.

Drs. Joel Topf and Anna Gaddy from the Nephrology Times editorial board discuss highlights of #NKFClinicals (so far) on day 2 of the conference. #nephrology

Discover research and other updates from NKF SCM26 on Nephrology Times.

Joel Topf, MD, and Anna Gaddy, MD, report on NKF Spring Clinicals 2026, day 1. Be sure to watch for more conference highlights at nephtimes.com! #nephrology #NKFClinicals

Joel Topf, MD, shares highlights from the 2026 KIDNEYcon nephrology conference.

Sarah Tolson examines the financial and operational strain created by Medicare Advantage plans' prior authorization requirements for dialysis.

Notable kidney care professionals, including Katalin Susztak, Ron Wald, and Brad Rovin, will be honored at the National Kidney Foundation Spring Clinical Meetings 2026.

Brigitte Schiller, MD, of Fresenius Medical Care discusses the barriers that have constrained adoption of nocturnal home hemodialysis and how they might be overcome.

After several years of breakthroughs, we seem to have the tools to make widespread chronic kidney disease (CKD) remission a reality, yet several barriers remain.

Nurse and educator Debra Hain discusses the underlying causes of gaps in rural kidney care gaps and how to bridge them.

In this recurring section, Nephrology Times asked five nephrology fellows: What would you tell an internal medicine resident considering nephrology?

Kirk Campbell, MD, president of the National Kidney Foundation, discusses the FDA's approval of sparsentan to treat focal segmental glomerulosclerosis (FSGS).

Glucagon-like peptide-1 (GLP-1) receptor agonists like semaglutide are beneficial for chronic kidney disease (CKD), but cost and other barriers to use are a challenge.

Salvatore Viscomi, MD, CEO of Carna Health, discusses how the company responsibly scales AI-enabled chronic kidney disease screening around the globe.

Researchers Vlado Perkovic, MBBS, PhD, and Dana Rizk, MD, are featured in a discussion of sibeprenlimab and other B-cell therapies for IgA nephropathy (IgAN).

Anna Gaddy, MD, of the Nephrology Times editorial board discusses the patient’s perspective on autosomal dominant polycystic kidney disease (ADPKD) diagnosis and management.

Maria Litchfield of Thermo Fisher Scientific discusses barriers that kidney transplant recipients face in maintaining immunosuppressive therapy and how clinicians can help.

Sarah Tolson advises nephrology practices on how to build operational resilience to handle change and crises without disruption to financial stability or patient care.

Artificial intelligence (AI) is making its way into clinical practice. This article presents experts' opinions on how nephrologists can best prepare.

Natalia Barolín, RN, senior health policy advisor at Johns Hopkins School of Nursing, discusses how a proposed student loan rule change could affect nursing.

Hiddo Heerspink, PhD, discusses how shifts in trial design, methodology, and regulatory attitudes are helping to advance chronic kidney disease (CKD) research.

Nephrology Times spoke to Katherine Kwon, program chair of the Renal Physicians Association 2026 Annual Meeting, about what the event offers nephrology professionals.

Anna Gaddy, MD, of the Nephrology Times editorial board discusses the patient’s perspective on autosomal dominant polycystic kidney disease (ADPKD) diagnosis and management.